A Phase 1, Prospective, Open Label, Two Period, Fixed Sequence, Dose-Escalation Study of the PK and Safety of BAX 826 (PSA-rFVIII) in Previously Treated Patients With Severe (FVIII <1%) Hemophilia A
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2017
At a glance
- Drugs BAX 826 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Baxalta; Shire
- 10 Jun 2017 Biomarkers information updated
- 22 May 2017 Results published in a Xenetic Biosciences media release.
- 18 Apr 2017 Status changed from recruiting to completed.